A robust enzyme-linked immunosorbent assay to measure serum ramucirumab concentrations.
Bioanalysis
; 13(7): 565-574, 2021 Apr.
Article
en En
| MEDLINE
| ID: mdl-33769095
ABSTRACT
Aim:
Ramucirumab, an anti-VEGFR2 monoclonal antibody, has been approved for the treatment of metastatic gastric and colorectal cancer. An assay measuring ramucirumab serum concentrations was needed to investigate its pharmacokinetics and concentration-response relationship.Results:
An ELISA was developed and validated according to the international guidelines for ligand-binding assays. Ramucirumab calibration standards ranged from 0.125 to 40 mg/l. Low, middle and high quality controls were spiked at 0.2, 4 and 8 mg/l, respectively. The limits of quantification were established to be 0.125 and 10 mg/l for LLOQ and ULOQ, respectively. No cross-reactivity with anti-VEGF or anti-EGFR was detected.Conclusion:
This in-house-developed ELISA is sensitive, accurate, reproducible and suitable for pharmacokinetic studies of ramucirumab.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Ensayo de Inmunoadsorción Enzimática
/
Neoplasias Colorrectales
/
Anticuerpos Monoclonales Humanizados
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Revista:
Bioanalysis
Año:
2021
Tipo del documento:
Article
País de afiliación:
Francia